IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
19 hedge funds and large institutions have $41.7M invested in IO Biotech in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
74% more capital invested
Capital invested by funds: $24M → $41.7M (+$17.7M)
27% more funds holding
Funds holding: 15 → 19 (+4)
2.54% more ownership
Funds ownership: 42.49% → 45.03% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.55M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.63M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.34M |
| 4 |
AC
Armistice Capital
New York
|
+$3.78M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
-$85.5K |
| 2 |
STA
Summit Trail Advisors
New York
|
-$85.5K |
| 3 |
Renaissance Technologies
New York
|
-$78.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$73.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$25.5K |
IOBT Hedge Fund Activity: Q3 2023 in Review
19 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q3 2023, worth a combined $41.7M — up 74% from $24M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IOBT positions and 4 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vivo Capital, adding an estimated $5.55M. The largest seller was Aureus Asset Management, exiting entirely with an estimated $85.5K sold.
- 19 institutional investors held IO Biotech (IOBT) as of Q3 2023, up from 15 in Q2 2023.
- Funds reported $41.7M of IO Biotech stock for Q3 2023, up 74% quarter-over-quarter.
- 8 funds opened new IO Biotech positions in Q3 2023 and 4 closed out, a net change of +4 holders.
- The largest IO Biotech buyer in Q3 2023 was Vivo Capital, an estimated $5.55M added.
- The largest IO Biotech seller in Q3 2023 was Aureus Asset Management, an estimated $85.5K sold.
Based on aggregated 13F filings for Q3 2023.